Skyhawk Therapeutics, Inc.
Clinical trials sponsored by Skyhawk Therapeutics, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill aims to tame Huntington's disease by targeting toxic proteins Results expected May 2027 (estimated)
-
Hope for Huntington's: new pill aims to tame harmful proteins
Disease control By invitation onlyThis study tests an oral drug called SKY-0515 in 500 adults with Huntington's disease who have already completed a prior study of the same drug. The goal is to see if the drug can safely lower harmful proteins and improve symptoms over the long term. Participants must be 25 or ol…
Phase 2/3 • Sponsor: Skyhawk Therapeutics, Inc. • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New pill aims to tame Huntington's disease by targeting toxic proteins
Disease control OngoingThis study tests an oral drug called SKY-0515 in 120 adults with Huntington's disease. The goal is to see if it can lower harmful proteins in the blood, slow brain changes, and improve symptoms. Participants must be 25 or older with a confirmed genetic diagnosis and a certain lev…
Phase 2/3 • Sponsor: Skyhawk Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC